Guillain-Barré Syndrome Clinical Trial
Official title:
A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome
This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.
The study will enroll approximately 12 subjects into one cohort, with subjects receiving 75 mg/kg of ANX005, a dose shown to be safe and well-tolerated as monotherapy and that provides a meaningful level of exposure to be tested in combination with IVIg. Dosing of IVIg will be administered as is the current standard of care (0.4 g/kg/day x 5 days) and ANX005 will be administered concurrently, beginning on Day 1 or 2 of the treatment period. Subjects will be followed for 6 months after treatment for observation and evaluation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02221271 -
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
|
Phase 3 | |
| Withdrawn |
NCT05494619 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
|
Phase 3 | |
| Withdrawn |
NCT03773328 -
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-BarreĢ Syndrome (GBS)
|
Phase 1 | |
| Active, not recruiting |
NCT01582763 -
International Guillain-Barré Syndrome Outcome Study
|
||
| Recruiting |
NCT05461898 -
RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome
|
N/A | |
| Completed |
NCT02780570 -
Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients
|
Phase 2 | |
| Completed |
NCT02342184 -
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
|
Phase 3 |